Andy Pasternak

Andy Pasternak is a member of our Healthcare & Life Sciences practice, previously serving as a Senior Partner and leader for the Americas. He was also a member of the Mergers & Acquisitions practice.

Andy has over 25 years of experience as a consultant and an executive. He advises boards of directors, CEOs and their leadership teams on their most pressing business challenges and opportunities.

At Bain, Andy has worked with large pharmaceutical companies, medical technology companies, biotechnology firms, private investment funds, NGOs and government agencies. He holds deep expertise in growth strategy, market entry, competitive strategy, M&A, organizational design and executive/board governance, operational strategy and performance improvement. In the biopharmaceutical space, Andy has worked across a wide range of specialty therapeutic areas (including rare diseases) and functions, including commercial, operations and R&D.

Recently, Andy served as Executive Vice President, Chief Strategy Officer for Horizon Therapeutics, a biotechnology company focused on serious, rare autoimmune and inflammatory diseases. In this role, he was responsible for corporate strategy, M&A / business development, commercial development, and portfolio management, and he played a central role in the $28 billion acquisition of Horizon by Amgen, Inc. in 2023.

Andy currently serves on the Board of Directors of Endo, Inc., a specialty pharmaceutical company, and as Chairman of the Board of Context Therapeutics, an oncology-focused biotechnology company. Andy is also an adjunct lecturer in the healthcare program at the Kellogg School of Management at Northwestern University, where he teaches a course about the biopharmaceutical industry.

Andy earned an MBA from the University of Chicago Graduate School of Business and a B.A. in economics from Northwestern University.